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ABSTRACT: Here, we predicted the potential halogen
bonding interaction between compound 2 and the 5-
hydroxytryptamine 2B (5-HT2B) receptor and systematically
assessed this interaction via structure−activity relationship
analysis and molecular dynamics simulations. A physics-based
computational protocol was then developed to further explore
the opportunity of “designing in” halogen bonding inter-
actions in structure-based ligand design for the 5-HT2B
receptor, which not only facilitated the identification of
previously uncharacterized halogen bonds in known 5-HT2B
ligands but also enabled the rational design of halogen bonding interactions for the optimization of 5-HT2B ligands. As a proof-
of-concept, a series of halogen-substituted analogues of doxepin was synthesized and evaluated, which showed improved in vitro
and in vivo potency.
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Halogen bonding is now recognized as an importantnoncovalent interaction in the protein−ligand binding
process.1−3 It is characterized as a directional and electrostati-
cally driven interaction between a crown of positive charge on
the outer side of a halogen atom, known as the σ-hole, and an
electrically negative site.4 Structural database survey studies
have revealed its common occurrence in biological systems.5,6
The concept of halogen bonding is now attractive in drug
discovery programs owing to its advantages for improving
drug−target binding affinity and for tuning ADME/T
properties.7 Although the importance and potential of halogen
bond interactions in protein−ligand binding are now widely
appreciated by theorists and computational chemistry
researchers, it is worth noting that our understanding in this
area results largely from serendipitous discoveries or post facto
analysis rather than from practical application in effective
designs from predictions.8 Recently, however, a few exciting
successful utilizations of halogen bonding interactions in lead
optimization programs have stimulated efforts to apply this
potentially powerful approach in rational drug design.9−11
Our aim in undertaking the present study was to explore the
potential of halogen bond interactions in structure-based
ligand design by using the 5-hydroxytryptamine 2B (5-HT2B)
receptor as a case study. We previously identified a novel series
of compounds (Figure 1A) with potent and selective 5-HT2B
antagonist activity.12 Here, we carried out structure−activity
relationship (SAR) analysis and molecular dynamics (MD)
simulations to explore a potential halogen bonding interaction
between the bromine-containing compound 2 and the 5-HT2B
receptor. We also developed a physics-based computational
protocol to systematically utilize halogen bonding interactions
for known 5-HT2B ligands. Our protocol successfully led to not
only the identification of potential halogen bonding
interactions in existing 5-HT2B ligands but also to design
ideas to exploit novel halogen bond interactions via specific
halogen substitutions. As an example case, we incorporated a
bromine substitution on doxepin to design compound 14,
which showed a 10-fold increase in binding affinity (Ki = 2.5
nM) and superior in vivo therapeutic potency.
In our previous study, the ethyl benzoate moiety of
compound 1 deeply buried into the inner part of the
hydrophobic binding pocket was predicted to form a hydrogen
bond with residue Thr1403.37 of the 5-HT2B receptor (Figure
1B), where the ethyl formate group of compound 1 appears to
be essential for such binding; its removal largely destroyed its
activity.12 A SAR study showed that the bromine-containing
analogue compound 2, although lacking the ability to hydrogen
bond with the aforementioned Thr1403.37, exhibited com-
parable binding activity with compound 1 (Figure 1A). Here,
by examining molecular docking poses, we found that
compound 2 could adopt another configuration in which the
bromobenzene ring flipped over and pointed toward the
exposed backbone carbonyl of Phe2175.38 on the opposite side
(Figure 1B). With the concept of halogen bond interactions in
mind, we predicted that compound 2 might form a halogen
bonding interaction between the bromine atom and the
carbonyl oxygen atom of Phe2175.38, which might contribute to
its potent binding affinity.
To estimate the potential of the predicted halogen bonding
interaction between compound 2 and the 5-HT2B receptor, we
synthesized a series of halogen-substituted compounds and
evaluated their antagonist activities in cellular function assays
(Table 1). Compared with unhalogenated compound 3,
introduction of halogen atoms with fluoride, chlorine, bromine,
and iodine enhanced the activity by factors of 4, 35, 46, and 70,
respectively (compounds 2 and 4−6, respectively), which
nicely follows the general trend for the strength order of
halogen bonding: F ≪ Cl < Br < I.13 However, replacing the
chlorine atom in compound 5 with a methyl group, which is a
hydrophobic group but lacks any σ-hole effect, led to a 10-fold
decrease in activity for compound 7. In addition, substitution
with a hydroxyl group abolished the activity of compound 8,
suggesting that it is not likely to introduce a hydrogen bond
interaction at this position for targeting the backbone carbonyl
of Phe2175.38. Radioligand binding assays were also performed
to determine their binding affinities; the results were consistent
with the cellular activities (Table 1).
MD simulations were carried out to investigate the structural
characteristics of this halogen bonding interaction. To account
for the contribution of σ-hole effects, we introduced a
positively charged extra point (EP) on the bromine atom in
compound 2 as described previously.14 A stable Br···O distance
of ∼3.08 Å and an almost optimal ∠C−Br···O angle of
∼173.7° were revealed in a 50 ns MD simulation (Figure 1C),
suggesting the formation of a halogen bond with the backbone
carbonyl of Phe2175.38.
We also synthesized compound 9 in which two bromine
substitutions were introduced on both ortho positions in the
phenyl ring to further support our prediction that the bromine
atom could favor the orientation toward residue Phe2175.38.
The IC50 value of compound 9 is 215.0 nM (Table 2). The
mildly reduced potency of compound 9 might result from the
steric clashes by the bromine substitution on the other ortho
position. Clearly, a weakened halogen bond with a deviated
distance and angle was observed during the MD simulation
(Figure S1). Although single ortho substitution for a large-
sized group would be favorable as for the ethyl formate group
in compound 1, substitutions on both ortho positions were not
additive due to a 27° twist angle between the phenyl-ring
planes in their individually optimal configurations in the
binding pocket (Figure S2). Thus, large-size substitutions on
the other ortho position would twist the phenyl-ring plane,
which finally affected the strength of the halogen bond with
Figure 1. Predicted halogen bonding interaction between compound
2 and the 5-HT2B receptor. (A) Chemical structures and binding
affinities of 1 and 2. (B) Comparison of the predicted binding modes
of 1 (blue) and 2 (yellow). (C) MD simulations of compound 2 in
complex with the 5-HT2B receptor.
Table 1. Validation of the Halogen Bonding Interaction in
Compound 2
ID R IC50 (nM)
a Ki (nM)
b
3 -H 1641.3 ± 221.2 151.3 ± 20.7
4 -F 403.4 ± 53.1 53.3 + 13.7
5 -Cl 46.9 ± 4.8 6.3 ± 0.9
2 -Br 35.4 ± 1.7 5.8 ± 1.2
6 -I 23.3 ± 3.7 1.7 ± 0.4
7 -CH3 459.4 ± 118.2 19.8 ± 4.8
8 −OH n.a.c 313.5 ± 43.0
aThe IC50 values were determined for each compound (mean ±
SEM) from two independent tests. bThe Ki values were determined
for each compound (mean ± SEM) from three independent tests.
cNot active, <50% inhibition at 10 μM concentration.
residue Phe2175.38. This is further supported by compounds 10
and 11 (Table 2). Additionally introducing small groups (a
fluorine atom in compound 10) on the other ortho position
had almost no effect on the activity (with an IC50 value of 74.9
nM). Instead, substitution with a larger group (the ethyl
formate group in compound 11) would bring steric clashes and
dramatically reduce the activity (with an IC50 value of 1962.5
nM). MD simulations also indicated that the halogen bonding
interaction is well maintained in compound 10 but is disrupted
in compound 11 (Figure S1).
We also developed a physics-based computational protocol
to systematically explore the opportunity of utilizing halogen
bonding interactions in the design of ligands for the 5-HT2B
receptor. From ChEMBL database (version 23, May 2017),
1113 known 5-HT2B ligands were initially docked into the
binding pocket, and halogen substitutions were then
introduced in silico to identify potential halogen bonding
interactions with the 5-HT2B receptor (Figure S3A). A chlorine
atom would be added to any unsubstituted aromatic carbon
atom of the ligand; note that only the protein backbone
carbonyl, which is the most frequently observed binding
partner in biomolecular halogen bonds,15 was considered here.
Each Car-Cl···O=C interaction pair was evaluated by the
defined geometry criteria (Figure S3B). Substitutions that met
the relaxed geometry criteria (d < 4 Å and θ > 120°)2,5 and
which produced no obvious steric clashes (distance < 2 Å)
with surrounding residues were retained for the next
optimization, which finally resulted in 1574 modeled
halogenated ligands to meet the halogen bonding criteria;
note that multiple halogen substitutions could be introduced
on different sites in one ligand. These complexes were
subjected to minimization and MM-PB/SA calculation with
the inclusion of EP on the chlorine atoms. There were 277
chlorine-substituted ligands predicted to form potential
halogen bonding interactions with the 5-HT2B receptor by
satisfying the precise geometry criteria (d < 3.27 Å and θ >
140°)8 and exhibiting favorable binding free energies (ΔG < 0)
related to their parent ligands (Table S1). Among these
chlorine-substituted ligands, 11 were found as already existing
5-HT2B ligands with published activities, thereby serving as
retrospective validations. Encouragingly, 9 of these 11 ligands
have increased activities compared with the parent ligands
(Table S2). The improved activities in these cases might result
from the halogen bonding, and none of these halogen bonding
interactions were characterized previously. Similar results were
also obtained for bromine substation (Tables S3 and S4).
Moreover, it was notable that our computational protocol
could identify the halogen bonds in both agonists and
antagonists of the 5-HT2B receptor (as illustrated in Figure
S4), suggesting considerable predictive power.
Here, we focused on the predicted potential substitution
sites for halogen bonding interactions in 21 FDA approved
drugs with known 5-HT2B activities (Table S5). More than half
of them belonged to two clusters: ergoline derivatives and
tricyclic antidepressants (TCAs) (Table 3). Ergoline deriva-
tives are a class of hemiterpenoid indole alkaloids. Acting as
ligands for various serotonin and dopamine receptors,
ergolines exert broad pharmacological actions and have been
used clinically for vasoconstriction, migraines, and Parkinson’s
disease.16 Consistent with the reported crystal structures of the
5-HT2B receptor complexed with ergotamine
17 and lysergic
acid diethylamide,18 the ergoline scaffold is anchored through
the salt-bridge with the carboxylate of Asp1353.32 and buried
into the hydrophobic pocket formed by the residues of
Val1363.33, Gly2215.42, Phe2175.38, Phe3416.52, and Val3667.39.
The indole ring points toward the exposed backbone carbonyl
of Phe2175.38, and chlorine substitution at the 3-position was
predicted to form a halogen bond with the residue Phe2175.38
(Table 3). TCAs are a class of drugs commonly used to relieve
depression. They are often highly promiscuous ligands with
nanomolar affinities at various GPCRs. The antagonist activity
against the 5-HT2B receptor was also reported for many TCAs.
In our predicted binding models, the amine moiety of TCAs
forms a salt-bridge with the residue Asp1353.32, and the
tricyclic ring sits deeply in the hydrophobic binding pocket and
packs against the aromatic side chains of the residues
Trp3376.48, Phe3406.51, and Phe3416.52; this resembles the
interaction observed in the crystal structure of the doxepin-
bound histamine H1 receptor.
19 On the basis of this binding
configuration, we predicted that a halogen bonding interaction
could be formed between residue Phe2175.38 and the
substituted chlorine atom on the phenyl ring as illustrated in
Table 3. Given emerging opportunities and concerns for the
clinical applications of 5-HT2B antagonists,
20,21 modification of
existing drugs to tune the binding preference against the 5-
HT2B receptor may be an effective strategy.
Table 2. Validation of the Binding Mode of Compound 2
ID R IC50 (nM)
a
2 -H 35.4 ± 1.7
9 -Br 215.0 ± 17.2
10 -F 74.9 ± 8.7
11 -COOEt 1962.5 ± 134.1
aThe IC50 values were determined for each compound (mean ±
SEM) from two independent tests.
Table 3. Design of Halogen Bonding Interactions with the
5-HT2B Receptor in FDA Approved Drugs
Interestingly, we found residues Phe2175.38 and Gly2215.42
were the most frequently targeted “hot spots” in the 5-HT2B
receptor, accounting for 75.8% of the predicted halogen
bonding interactions (Figure 2A). Examining the ligand
binding pocket, we found that Phe2175.38, Gly2215.42, and
Ala2255.46 are located on three consecutive turns of helix V
with side chains orientated toward the binding pocket (Figure
2B). Avoidance of side chain steric hindrance in Gly2215.42 and
Ala2255.46 leads to an exposed backbone carbonyl oxygen in
residues in the preceding turn (Phe2175.38 and Gly2215.42,
respectively) for interaction with the halogen atom. Sequence
alignment analysis further suggested that, although Phe5.38 or
Tyr5.38 is conserved in most monoamine GPCRs, Gly5.42 is only
conserved in the 5-HT2 receptors (Figure S5). Thus, the
interaction propensity with Phe5.38 might be unique for three 5-
HT2 receptors. Substitution of Gly
5.42 to a larger residue with a
bulk side chain would block the accessibility of the backbone
carbonyl in Phe5.38 (as illustrated in histamine H1 receptor in
Figure S6). For Gly5.42, the 5-HT2B and 5-HT2C receptors
might have higher propensity of interaction due to the A5.46S
substitution in the 5-HT2A receptor (Figure S5). The unique
structural features of residues Phe5.38 and Gly5.42 also make
possible the rational improvement of binding selectivity against
the 5-HT2 receptors. In addition, the designed halogen bonds
with the Phe5.38 and Gly5.42 residues tend to be geometrically
perpendicular to the shared hydrogen bonds with the
backbone amide in the succeeding helix turn, which is quite
consistent with the concept that halogen bonds in
biomolecular systems tend to be geometrically orthogonal
and energetically independent of hydrogen bonds that share
the same acceptor.22
As a proof-of-concept for halogen bonding in the design of
5-HT2B ligands, a series of halogen-substituted compounds
were synthesized based on doxepin, a widely used TCA (Table
3). Introducing chlorine and bromine substitutions brought 8-
and 10-fold improved binding affinities in compounds 13 and
14, respectively (Figure 3A), whereas introducing fluoride
substitution in compound 12 had no effect on the binding
affinity. MD simulation was carried out for compound 14
complexed with the 5-HT2B receptor, which showed the
formation of a halogen bond with the backbone carbonyl of
Phe2175.38 (Figure S7). The averaged Br···O distance during
50 ns MD simulation is 3.16 Å, and the averaged ∠C−Br···O
angle is 171.0°. We further evaluated the in vivo bioactivity of
compound 14 using a castor oil-induced diarrhea model in
mice.23 The 5-HT2B receptor was reported to regulate the
contraction of smooth muscle to mediate GI motility,24 and its
inhibition was shown to produce a benefit for abnormal
Figure 2. Halogen bonding interaction “hot spots” in the 5-HT2B
receptor. (A) Statistics of predicted halogen bond formation with the
backbone carbonyl of different residues in the 5-HT2B receptor. (B)
Environment of the residues of Phe2175.38, Gly2215.42, and Ala2255.46
in the binding pocket in the 5-HT2B receptor.
Figure 3. Halogen-substituted doxepin exhibited improved potency
both in vitro and in vivo. (A) Binding affinities of doxepin and
compounds 12−14 against the 5-HT2B receptor. The Ki values were
determined for each compound (mean ± SEM) from three
independent tests. (B) Diarrhea score in castor oil-induced diarrhea
model. (C) Fecal weight in castor oil-induced diarrhea model.
defecation.25,26 At the same oral dosage (10 mg/kg), we found
compound 14 exhibited superior therapeutic efficiency
compared with doxepin, significantly improving stool con-
sistency (Figure 3B) and normalizing fecal output (Figure 3C).
Moreover, decreases in body weight were also strongly
attenuated by compound 14 (Figure S8).
In this study, we evaluated halogen bonding interactions in
the 5-HT2B receptor and used the information we gathered to
design new ligands with increased binding activity. Previously
uncharacterized halogen bonds in known 5-HT2B ligands were
identified, and novel halogen bonding interactions were
designed for further ligand optimization. Halogen atoms have
been classically incorporated in drug development to increase
membrane permeability and metabolic stability. Recent studies
have highlighted the importance of halogen bond interactions
contributing to 5-HT ligand binding.27,28 Moreover, the
potential role of halogen atoms as hydrogen bond acceptors
has also been noted,29 which deserves further investigation
both computationally and experimentally. Nevertheless, there
is great potential to utilize halogen atoms in structure-based
drug design in general if those interactions can be accurately
predicted and incorporated. Our developed protocol has
exhibited encouraging prediction of the binding energies
between the parent ligands and their halogenated substitutes
(Figure S9), thus providing the opportunity to “design in”
halogen bond interaction in the lead optimization process.
Doxepin is a commonly used TCA with moderate 5-HT2B
antagonist activity.30 Recent studies have suggested that it also
may be effective for patients with diarrhea-predominant
irritable bowel syndrome (IBS-D) and promoted it into
clinical trials.31 Although the pathogenic mechanism of IBS-D
is not fully understood, the 5-HT2B receptor was believed to
play an important role and could be regulated to improve both
visceral hypersensitivity and abnormal defecation in IBS-D
models.24−26,32 Our design of compound 14, by successfully
exploiting halogen bonding interactions, brings a 10-fold
increased binding affinity with the 5-HT2B receptor. Moreover,
compound 14 had superior in vivo therapeutic efficiency in a
mouse model of diarrhea, making it a promising preclinical
candidate. Certainly, further investigation on the PK/ADME
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